Current status: Answered by Neil Gray on 2 April 2024
To ask the Scottish Government whether the necessary genetic tests are available in all NHS board areas to enable the prescribing of Olaparib to treat prostate cancer.
Prostate BRCA1/2 genetic testing to support access to Olaparib is available to all eligible patients in Scotland. The testing has been implemented with funding from Scottish Government in 2023-24.
In Scotland genomic testing is provided through a network of four NHS laboratories which are commissioned through NHS National Services Division (NSD), part of NHS National Services Scotland. The laboratories work in conjunction with the Scottish Strategic Network for Genomic Medicine (SSNGM) to deliver a directory of genomic tests for people across Scotland as a whole and to ensure that testing is embedded within end-to-end clinical pathways.